Surgery vs. new Weight-Loss drugs: which works best for severe obesity?
NCT ID NCT06803888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares three treatments for severe obesity: two types of bariatric surgery (gastric bypass and sleeve gastrectomy) and two newer weekly injectable medications (semaglutide and tirzepatide). About 125 adults with a BMI of 35 or higher will be followed for one year to see which approach leads to the greatest weight loss. The goal is to help doctors and patients choose the best treatment option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Cleveland Clinic
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test